BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BC Extra | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BC Week In Review | Oct 27, 2017
Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...
BC Week In Review | Sep 15, 2017
Company News

J&J drops Achillion HCV deal

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178 . J&J said it decided to discontinue development of JNJ-4178 “in light of...
BC Extra | Sep 12, 2017
Company News

Achillion down after J&J drops HCV compound

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $1.08 (22%) to $3.83 Monday after Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal to develop and commercialize HCV therapies, including triplet therapy JNJ-4178 . J&J said it decided to discontinue...
BC Week In Review | Dec 30, 2016
Clinical News

JNJ-4178: Ph IIb OMEGA-1 started

Achillion said Johnson & Johnson began the open-label, international Phase IIb OMEGA-1 trial to evaluate oral JNJ-4178 once daily for 6 or 8 weeks in about 300 patients without cirrhosis. JNJ-4178 comprises 800 mg AL-335...
BC Week In Review | Oct 3, 2016
Clinical News

AL-335: Interim Phase IIa data

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN, New Haven, Conn.) reported interim data from 4 cohorts of treatment-naive patients with chronic HCV genotype 1 infection in an open-label, New Zealand Phase IIa trial evaluating oral combinations of AL-335,...
BC Week In Review | Oct 3, 2016
Clinical News

Odalasvir: Interim Phase IIa data

Achillion reported interim data from 4 cohorts of treatment-naive patients with chronic HCV genotype 1 infection in an open-label, New Zealand Phase IIa trial evaluating oral combinations of AL-335 , odalasvir and Olysio simeprevir. In cohort...
BC Extra | Sep 23, 2016
Clinical News

J&J six-week combo cures all HCV patients in Phase II cohort

All 20 patients receiving a six-week course of a triple-combination therapy from Johnson & Johnson (NYSE:JNJ) to treat HCV genotype 1 infection achieved an SVR12 in a Phase II study, according to J&J's partners Achillion...
BioCentury | Feb 29, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/26 cls Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Upgrade Outperform (from neutral) 10% $7.35 Skorney upgraded and maintained his...
Items per page:
1 - 10 of 14